Prostate Cancer study: AAA617
Official title Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
ClinicalTrials.gov ID: NCT05803941
What this study is testing
What is AAA617?
AAA617 is an investigational radioligand therapy being studied for prostate cancer. AAA617 is designed to bind to PSMA on prostate cancer cells and deliver targeted radiation from lutetium-177.
Also referred to as lutetium (177Lu) vipivotide tetraxetan, [177Lu]Lu-PSMA-617, 177Lu-PSMA-617.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to learn about any long‑term risks or serious side effects of lutetium‑177 PSMA‑617 in people with prostate cancer.
- Who it's for
- Adults with prostate cancer who have already gotten at least one dose of lutetium‑177 PSMA‑617 in earlier trials.
- What's involved
- Participants will have regular check‑ups, lab tests and other safety assessments to see if any problems develop over time.
- Time commitment
- The study follows participants for an extended period (months to years) with periodic clinic visits for monitoring.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 100, men only
You may be able to join if
- Signed informed consent must be obtained prior to participation in the study
- Must have received at least one dose of AAA617 within an treatment, Phase I-IV Novartis sponsored clinical trial in prostate cancer and have...
You likely can't join if
- \- Inability to complete the needed investigational examinations due to any reason.
The study team makes the final eligibility decision.
Where it is enrolling
- Scottsdale, Arizona, United States
- Orange, California, United States
- Santa Monica, California, United States
- Aurora, Colorado, United States
- Hartford, Connecticut, United States
- Washington D.C., District of Columbia, United States
- Jacksonville, Florida, United States
- Athens, Georgia, United States
- Fort Wayne, Indiana, United States
- New Orleans, Louisiana, United States
- Royal Oak, Michigan, United States
- Rochester, Minnesota, United States
- Jackson, Mississippi, United States
- St Louis, Missouri, United States
- Omaha, Nebraska, United States
- The Bronx, New York, United States
- Durham, North Carolina, United States
- Cleveland, Ohio, United States
- Pittsburgh, Pennsylvania, United States
- Dallas, Texas, United States
+ 28 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18 years to 100 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Scottsdale, Arizona, United States; Orange, California, United States; Santa Monica, California, United States; Aurora, Colorado, United States; Hartford, Connecticut, United States; Washington D.C., District of Columbia, United States and 42 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.